Johal Ama, Haria Priya, Manek Seema, Joury Easter, Riha Renata
Oral Growth and Development, Institute of Dentistry, Queen Mary University of London, UK.
Sleep and Respiratory Medicine, Edinburgh Royal infirmary, UK.
J Clin Sleep Med. 2017 Feb 15;13(2):175-182. doi: 10.5664/jcsm.6440.
To compare the effectiveness of a custom-made (MRDc) versus ready-made (MRDr) mandibular repositioning devices (MRD) in the management of obstructive sleep apnea (OSA).
A randomized crossover trial design was adopted in which patients with a confirmed diagnosis of OSA were randomly allocated to receive either a 3-month period of ready-made or custom-made MRD, with an intervening washout period of 2 weeks, prior to crossover. Treatment outcomes included both objective sleep monitoring and patient-centered measures (daytime sleepiness, partner snoring and quality of life).
Twenty-five patients, with a mild degree of OSA (apnea-hypopnea index of 13.3 [10.9-25] events/h) and daytime sleepiness (Epworth Sleepiness Scale of 11 [6-16]), completed both arms of the trial. The MRDc achieved a complete treatment response in 64% of participants, compared with 24% with the MRDr (p < 0.001). A significant difference was observed in treatment failures, when comparing the MRDr (36%) with the MRDc (4%). Excessive daytime sleepiness (Epworth Sleepiness Scale ≥ 10) persisted in 33% (MRDc) and 66% (MRDr) of OSA subjects, following treatment. A statistically significant improvement was observed in quality of life scales following MRDc therapy only. Significant differences were observed in relation to both the number of nights per week (p = 0.004) and hours per night (p = 0.006) between the two different designs of device.
The study demonstrates the significant clinical effectiveness of a custom-made mandibular repositioning device, particularly in terms of patient compliance and tolerance, in the treatment of OSA.
比较定制式(MRDc)与成品式(MRDr)下颌重新定位装置(MRD)在阻塞性睡眠呼吸暂停(OSA)治疗中的有效性。
采用随机交叉试验设计,确诊为OSA的患者被随机分配接受为期3个月的成品式或定制式MRD治疗,在交叉治疗前有2周的洗脱期。治疗结果包括客观睡眠监测和以患者为中心的指标(日间嗜睡、伴侣打鼾情况和生活质量)。
25例轻度OSA患者(呼吸暂停低通气指数为13.3[10.9 - 25]次/小时)和日间嗜睡患者(爱泼沃斯嗜睡量表评分为11[6 - 16])完成了试验的两个阶段。MRDc使64%的参与者获得了完全治疗反应,而MRDr为24%(p < 0.001)。比较MRDr(36%)和MRDc(4%)时,观察到治疗失败率有显著差异。治疗后,33%(MRDc)和66%(MRDr)的OSA患者仍存在日间过度嗜睡(爱泼沃斯嗜睡量表≥10)。仅在MRDc治疗后,生活质量量表有统计学意义的改善。两种不同设计的装置在每周夜晚数量(p = 0.004)和每晚小时数(p = 0.006)方面均观察到显著差异。
该研究证明了定制式下颌重新定位装置在治疗OSA方面具有显著的临床有效性,特别是在患者依从性和耐受性方面。